Scott Russell
President, Chief Executive Officer

Mr. Russell brings over 30 years of leadership experience across medical device innovation, engineering, intellectual property development, marketing, and executive management. He previously served as President and CEO of SeptRx, Inc., a pioneering company in PFO closure technologies, and as interim CEO of SuperRenal, a company focused on protecting patients from contrast-induced nephropathy during interventional procedures.

Earlier in his career, Mr. Russell was Director of Advanced Device Concepts at Cordis/NDC (a Johnson & Johnson company), where he led the development and commercialization of several market-defining products, including the SMARTeR stent, the TrapEase and OptEase vena cava filters, and the Enterprise neurovascular stent. He also spearheaded the spin-out of two successful startups from J&J: Portaero, Inc., an interventional pulmonology company, and SeptRx, Inc.

A recognized authority in Nitinol technology, Mr. Russell is a past Chairman of the International Society of Shape Memory and Superelastic Technologies. He holds over 75 issued and granted patents in medical devices and advanced materials and has authored more than 20 scientific publications.

Amir Belson, M.D.
Founder, Chief Technology Officer

Dr. Belson is a physician, innovator, and serial entrepreneur with a track record of founding and scaling multiple successful medical device companies. His ventures include NeoGuide Systems (acquired by Intuitive Surgical), Vascular Pathways (acquired by C.R. Bard), and ZipLine Medical (acquired by Stryker). He is also the founder of Venocare, Qool Therapeutics, Radiaction Medical, Modular Surgical, and PAFA, each pioneering breakthroughs in vascular intervention, therapeutic hypothermia, radiation protection, minimally invasive surgery, and atrial fibrillation ablation technologies, respectively.

In addition to his entrepreneurial achievements, Dr. Belson serves on the boards of Relimetrics and QT Vascular. He graduated cum laude from the School of Medicine at the Technion – Israel Institute of Technology, completed his pediatric residency at Dana Children’s Hospital in Tel Aviv, and pursued a pediatric nephrology fellowship at Lucile Packard Children’s Hospital at Stanford University. Prior to his move to the United States, he served as a flight surgeon in the Israeli Air Force’s elite rescue unit. Dr. Belson also completed a research fellowship with Stanford’s prestigious Biomedical Technology Innovation Program.

He is the author of 34 medical publications and abstracts and holds over 750 issued and pending patents, reflecting a lifelong commitment to advancing medical innovation.

Mark Caires
Chief Financial Officer

Mark Caires brings over 30 years of strategic financial leadership to Emboline, with a proven track record in scaling venture-backed medical device companies through multiple stages of growth, fundraising, and M&A. He currently serves as Chief Financial Officer, where he oversees all financial, administrative, and operational functions, helping guide the company toward commercialization and strategic inflection points.

Prior to joining Emboline, Mark held senior financial roles at several high-growth medtech companies, At Silk Road, he played a key role in building financial systems and leading the company through clinical development, fundraising rounds, and preparation for IPO. Earlier in his career, he served in executive finance roles at Broncus Technologies and SpotLife (acquired by Logitech), where he was instrumental in raising over $140 million combined in capital and completing successful exits and spinouts.

Mark has deep expertise in financial modeling, M&A due diligence, and regulatory readiness, including preparing the MD&A for an S-1 filing with the SEC. He has managed finance, HR, IT, and facilities across multiple companies, successfully implementing enterprise systems, executing workforce transitions, and securing federal and venture funding.

With over $200 million in financings across his career, Mark’s ability to drive operational excellence while navigating complex capital and regulatory environments makes him a vital strategic asset to Emboline as the company advances toward pivotal value-creating milestones.

Laura Brenton
Senior Vice President, Clinical and Medical Affairs

Ms. Brenton brings over 25 years of leadership experience in the medical device industry, with a deep focus on clinical development, regulatory strategy, and global commercialization. Throughout her career in the life sciences, she has successfully led product development initiatives from pre-clinical stages through launch, driving market entry across Europe and South America and contributing to multiple acquisitions by major healthcare companies.

Before joining Emboline, Ms. Brenton served as Vice President of Clinical Affairs at Polares Medical, a clinical-stage MedTech company advancing transcatheter mitral valve therapies. Prior to that, she held senior leadership positions at several prominent structural heart companies, overseeing clinical, regulatory, and medical affairs functions, as well as spearheading physician training programs and business development initiatives.

At Emboline, Ms. Brenton leads all aspects of clinical development and field operations, managing the company’s global clinical studies and supporting strategic growth initiatives. She holds a degree from Wayne State University in Detroit, Michigan.

Stephen Kleshinski
Senior Vice President, Research

Mr. Kleshinski is a cardiovascular device industry veteran with over 40 years of experience in the development of cardiovascular, neurovascular and orthopedic devices. Before joining Emboline, he was engaged with Nfocus Neuromedical, which was subsequently purchased by Covidien. Prior to that, he held the position of Vice President of Strategic Development at Nitinol Devices & Components and earlier as Director of Advanced Device Concepts at Cordis/NDC (a Johnson & Johnson Company. He was hired as the Executive Vice President at Afferent Corporation, a neurotherapeutic device company and was the founding employee of NMT Medical responsible for all R&D activities at NMT from 1986 to 2000. Mr. Kleshinski received a BA in Sociology from the College of Steubenville, followed by three years of postgraduate studies in anatomy, physiology, and histology at Northeastern University, further followed by ten years of academic research work in neurosurgical research, orthopedic biomechanics, and interventional radiology, at Beth Israel Hospital/Harvard Medical School. He was an early pioneer in the development of Nitinol-based cardiovascular implants and has designed or developed nine[1] devices including the Simon Nitinol Vena Cava Filter, the SNF-SL filter product, the Symphony Nitinol stent, the Recovery removal vena cava filter, the CardioSeal cardiac septal repair device, the Phase One Medical Vena Cava Filter, the Vici venous stent, the SeptRx PFO occluder, and the Emboliner cerebral protection device. Mr. Kleshinski has over 50 issued and pending patents for medical devices and eight scientific publications.

Eric Storne
Vice President, Marketing and Clinical Relations

Mr. Storne brings over 30 years of expertise in product design, development, commercialization, and marketing, with the past two decades dedicated to advancing medical device technologies. Prior to joining Emboline, he served as Vice President of Marketing and Clinical Relations at ZipLine Medical, a leader in wound closure technology acquired by Stryker in 2019. Earlier, he was Vice President of Marketing at NeoGuide Systems, where he helped drive the development of a groundbreaking platform for minimally invasive robotic surgery, leading to the company’s acquisition by Intuitive Surgical in 2009. At Carl Zeiss Meditec and Sunrise Technologies, he led product management teams for therapeutic and diagnostic devices in the ophthalmology space.

Before his work in medical devices, Mr. Storne held marketing, product management, and design engineering roles at KLA Instruments/KLA-Tencor, Kaiser Electronics, and General Electric, building a strong foundation in advanced technology markets.

Mr. Storne holds a Bachelor of Science degree in Optical Engineering from the University of Rochester and an M.B.A. from Santa Clara University. He is an inventor with more than 50 issued and pending patents in the medical device field, reflecting a career-long commitment to innovation and market success.

Matt Davis
Vice President, Product Development

Mr. Davis brings over 15 years of leadership experience in product design, development, and manufacturing within the medical device industry. He joined Emboline following his role as Director of Program Management at Nordson Medical, where he was instrumental in driving cross-functional programs and delivering complex technologies to market. During his tenure, he also helped establish and scale Nordson Medical’s global footprint with new offices in Rosh Ha’Ayin, Israel, and Galway, Ireland.Mr. Davis has a proven track record in bringing innovative, high-value medical technologies from concept through commercialization. His expertise includes the development of single-use disposable devices, balloon and steerable catheters, and other complex delivery systems. He has supported product launches across multiple clinical specialties, including structural heart, gastrointestinal, neurological, endoscopic, urologic, gynecological, implantable devices, and drug delivery—demonstrating a strong ability to navigate technical complexity and regulatory pathways in high-growth markets.Earlier in his career, he served as a Systems Engineer at Pratt & Whitney Rocketdyne, contributing to advanced aerospace programs. Mr. Davis holds a Bachelor of Science in Mechanical Engineering from California Polytechnic State University, San Luis Obispo, where he graduated with honors.

Will Michul
Vice President, Quality and Regulatory Affairs

Mr. Michul leads Emboline’s Quality and Regulatory efforts with a highly adaptive, results-driven approach backed by deep expertise across a wide range of medical device technologies. Prior to joining Emboline, he served as Senior Quality Manager at Cannon Quality Group, a premier consulting firm specializing in Quality Assurance and Engineering solutions for the medical device industry. During his tenure, Mr. Michul successfully collaborated with over 50 companies, helping to develop, implement, and optimize critical quality systems. He holds a Bachelor of Science degree in Materials Engineering from California Polytechnic State University, San Luis Obispo.